329 related articles for article (PubMed ID: 30630983)
1. CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.
Prieto-Torres L; Rodriguez-Pinilla SM; Onaindia A; Ara M; Requena L; Piris MÁ
Haematologica; 2019 Feb; 104(2):226-235. PubMed ID: 30630983
[TBL] [Abstract][Full Text] [Related]
2. CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L; Zain J; Rosen ST; Querfeld C
Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
[TBL] [Abstract][Full Text] [Related]
3. How I treat primary cutaneous CD30
Shinohara MM; Shustov A
Blood; 2019 Aug; 134(6):515-524. PubMed ID: 31164331
[TBL] [Abstract][Full Text] [Related]
4. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
[TBL] [Abstract][Full Text] [Related]
5. Nodal Involvement by CD30
Lezama LS; Gratzinger D
Arch Pathol Lab Med; 2018 Jan; 142(1):139-142. PubMed ID: 29257929
[TBL] [Abstract][Full Text] [Related]
6. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
[TBL] [Abstract][Full Text] [Related]
7. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.
Bekkenk MW; Geelen FA; van Voorst Vader PC; Heule F; Geerts ML; van Vloten WA; Meijer CJ; Willemze R
Blood; 2000 Jun; 95(12):3653-61. PubMed ID: 10845893
[TBL] [Abstract][Full Text] [Related]
8. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
[TBL] [Abstract][Full Text] [Related]
9. A Review of Primary Cutaneous CD30
Chen C; Gu YD; Geskin LJ
Hematol Oncol Clin North Am; 2019 Feb; 33(1):121-134. PubMed ID: 30497669
[TBL] [Abstract][Full Text] [Related]
10. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
11. A Case-Based Review of Cutaneous CD30-Positive Lymphoproliferative Disorders.
Felts C; Tjarks BJ
S D Med; 2022 Sep; 75(9):402-409. PubMed ID: 36881825
[TBL] [Abstract][Full Text] [Related]
12. Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
Davick JJ; Mutgi KAJ; Wanat KA; Link BK; Liu V
J Cutan Pathol; 2017 Aug; 44(8):703-712. PubMed ID: 28497585
[TBL] [Abstract][Full Text] [Related]
13. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
Kummer JA; Vermeer MH; Dukers D; Meijer CJ; Willemze R
J Invest Dermatol; 1997 Nov; 109(5):636-40. PubMed ID: 9347791
[TBL] [Abstract][Full Text] [Related]
14. DUSP22-IRF4 Rearranged CD30-Positive Primary Cutaneous Lymphoproliferative Disorder With Gamma/Delta Phenotype.
Fattah YH; Crasto D; Liu SS; Linhares Y; Kerdel F; Hanly A; Karai LJ
Am J Dermatopathol; 2023 Dec; 45(12):831-834. PubMed ID: 37883980
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment.
Willemze R; Beljaards RC
J Am Acad Dermatol; 1993 Jun; 28(6):973-80. PubMed ID: 8388410
[TBL] [Abstract][Full Text] [Related]
16. Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders.
Sciallis AP; Law ME; Inwards DJ; McClure RF; Macon WR; Kurtin PJ; Dogan A; Feldman AL
Mod Pathol; 2012 Jul; 25(7):983-92. PubMed ID: 22388754
[TBL] [Abstract][Full Text] [Related]
17. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.
Kempf W
J Cutan Pathol; 2006 Feb; 33 Suppl 1():58-70. PubMed ID: 16412214
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous CD30(+) lymphoproliferative disorders.
Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
[TBL] [Abstract][Full Text] [Related]
19. CD30+ lymphoproliferative disorders of the skin: still an open question.
Alaibac M; Zarian H; Russo I; Peserico A
G Ital Dermatol Venereol; 2012 Dec; 147(6):545-52. PubMed ID: 23149700
[TBL] [Abstract][Full Text] [Related]
20. CD30+ T-cell lymphoproliferative disorders.
Martin JM; Wu H; Barta SK
Chin Clin Oncol; 2019 Feb; 8(1):4. PubMed ID: 30525751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]